Stock Scorecard

Stock Summary for BioNexus Gene Lab Corp (BGLC) - $3.07 as of 5/12/2025 6:50:55 PM EST

Total Score

16 out of 30

Safety Score

30 out of 100

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BGLC

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BGLC

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BGLC

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BGLC

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BGLC (30 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BGLC

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness 4/30/2025 3:25:00 PM
Bitcoin Is Steel, Ethereum And Solana Are Balsa Wood And Clay, Warns Michael Saylor-Strategy Chair Says Leveraging ETH, SOL Could Lead To 'Catastrophe' - Grayscale Ethereum Mini Trust ( ETH ) Common units of fractional undivided beneficial interest ( ARCA:ETH ) 4/22/2025 4:07:00 AM
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory 4/15/2025 3:00:00 PM
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert - Apple ( NASDAQ:AAPL ) , American Shared Hospital ( AMEX:AMS ) 4/4/2025 10:18:00 AM
Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert - Apple ( NASDAQ:AAPL ) , American Shared Hospital ( AMEX:AMS ) 4/4/2025 10:18:00 AM
BioNexus Stock Pops As It Embraces Ethereum-Focused Treasury Strategy, Says It Is First On Nasdaq To Do So - Grayscale Ethereum Mini Trust ( ETH ) Common units of fractional undivided beneficial interest ( ARCA:ETH ) 3/6/2025 7:37:00 AM
Nasdaq-Listed BioNexus Becomes First Public Firm to Approve Ethereum Treasury 3/6/2025 3:42:00 AM
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. - BioNexus Gene Lab ( NASDAQ:BGLC ) 9/25/2024 3:31:00 PM
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. 9/25/2024 3:31:00 PM
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. - BioNexus Gene Lab ( NASDAQ:BGLC ) 9/13/2024 4:05:00 PM

Financial Details for BGLC

Company Overview
Ticker BGLC
Company Name BioNexus Gene Lab Corp
Country USA
Description BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.
Sector Name LIFE SCIENCES
Industry Name SERVICES-MEDICAL LABORATORIES
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 3.07
Price 4 Years Ago 255.60
Last Day Price Updated 5/12/2025 6:50:55 PM EST
Last Day Volume 381,629
Average Daily Volume 1,277,777
52-Week High 7.50
52-Week Low 2.01
Last Price to 52 Week Low 52.74%

Valuation Measures
Trailing PE N/A
Industry PE 266.31
Sector PE 49.07
5-Year Average PE -33.75
Free Cash Flow Ratio 1.26
Industry Free Cash Flow Ratio 32.04
Sector Free Cash Flow Ratio 31.66
Current Ratio Most Recent Quarter 3.81
Total Cash Per Share 2.44
Book Value Per Share Most Recent Quarter 4.63
Price to Book Ratio 0.58
Industry Price to Book Ratio 2.47
Sector Price to Book Ratio 30.44
Price to Sales Ratio Twelve Trailing Months 0.50
Industry Price to Sales Ratio Twelve Trailing Months 2.36
Sector Price to Sales Ratio Twelve Trailing Months 25.43
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 1,796,600
Market Capitalization 5,515,562
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY -95.00%
Annual Earnings Growth 39.20%
Reported EPS 12 Trailing Months -0.90
Reported EPS Past Year -0.89
Reported EPS Prior Year -1.61
Net Income Twelve Trailing Months -1,842,904
Net Income Past Year -1,598,342
Net Income Prior Year -2,629,043
Quarterly Revenue Growth YOY 11.00%
5-Year Revenue Growth 137.09%
Operating Margin Twelve Trailing Months -26.80%

Balance Sheet
Total Cash Most Recent Quarter 4,377,427
Total Cash Past Year 4,377,427
Total Cash Prior Year 5,929,336
Net Cash Position Most Recent Quarter 4,377,427
Net Cash Position Past Year 4,377,427
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 8,322,804
Total Stockholder Equity Prior Year 9,657,852
Total Stockholder Equity Most Recent Quarter 8,322,804

Free Cash Flow
Free Cash Flow Twelve Trailing Months -2,478,655
Free Cash Flow Per Share Twelve Trailing Months -1.38
Free Cash Flow Past Year -2,461,249
Free Cash Flow Prior Year -1,450,993

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.04
MACD Signal -0.05
20-Day Bollinger Lower Band 2.09
20-Day Bollinger Middle Band 3.26
20-Day Bollinger Upper Band 4.42
Beta 1.72
RSI 46.78
50-Day SMA 39.74
150-Day SMA 0.00
200-Day SMA 76.63

System
Modified 5/12/2025 6:51:43 PM EST